HK1023513A1 - Compositions comprising conjugates of stable, active, human ob protein with antibody fc chain and methods - Google Patents

Compositions comprising conjugates of stable, active, human ob protein with antibody fc chain and methods

Info

Publication number
HK1023513A1
HK1023513A1 HK00102759A HK00102759A HK1023513A1 HK 1023513 A1 HK1023513 A1 HK 1023513A1 HK 00102759 A HK00102759 A HK 00102759A HK 00102759 A HK00102759 A HK 00102759A HK 1023513 A1 HK1023513 A1 HK 1023513A1
Authority
HK
Hong Kong
Prior art keywords
human
protein
conjugates
antibody
compositions
Prior art date
Application number
HK00102759A
Other languages
English (en)
Inventor
David N Brems
Donna L French
Margaret A Speed
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/059,467 external-priority patent/US20020019352A1/en
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of HK1023513A1 publication Critical patent/HK1023513A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Obesity (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
HK00102759A 1997-04-17 2000-05-09 Compositions comprising conjugates of stable, active, human ob protein with antibody fc chain and methods HK1023513A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84397197A 1997-04-17 1997-04-17
US09/059,467 US20020019352A1 (en) 1997-04-17 1998-04-14 Stable, active, human ob protein compositions and methods
PCT/US1998/007828 WO1998046257A1 (fr) 1997-04-17 1998-04-16 Compositions comprenant des conjugues de proteine ob humaine, active, stable avec une chaine fc d'anticorps et leurs procedes

Publications (1)

Publication Number Publication Date
HK1023513A1 true HK1023513A1 (en) 2000-09-15

Family

ID=26738785

Family Applications (1)

Application Number Title Priority Date Filing Date
HK00102759A HK1023513A1 (en) 1997-04-17 2000-05-09 Compositions comprising conjugates of stable, active, human ob protein with antibody fc chain and methods

Country Status (12)

Country Link
EP (1) EP0977583B1 (fr)
JP (1) JP4086908B2 (fr)
CN (1) CN1202862C (fr)
AT (1) ATE223229T1 (fr)
AU (1) AU7132798A (fr)
CA (1) CA2286098C (fr)
DE (1) DE69807679T2 (fr)
ES (1) ES2183351T3 (fr)
HK (1) HK1023513A1 (fr)
HU (1) HU226175B1 (fr)
IL (1) IL132380A0 (fr)
WO (1) WO1998046257A1 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
ES2217327T3 (es) * 1995-11-22 2004-11-01 Amgen Inc., Proteina ob para aumentar la masa de tejido magro.
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
SI2319928T1 (sl) 1998-10-23 2013-08-30 Kirin-Amgen, Inc. Dimerni trombopoietinski peptidni mimetiki, ki se veĺ˝ejo na receptor mp1 in imajo trombopoietinsko aktivnost
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
WO2000024418A1 (fr) * 1998-10-27 2000-05-04 Eli Lilly And Company Prevention de la perte de masse musculaire au moyen de ligands du recepteur de la leptine
CA2407956A1 (fr) * 2000-05-03 2001-11-08 Amgen Inc. Peptides modifies utilises comme agents therapeutiques
US20020090646A1 (en) * 2000-05-03 2002-07-11 Amgen Inc. Calcitonin-related molecules
BR0116803A (pt) * 2001-01-18 2004-02-17 Merck Patent Gmbh Proteìnas de fusão bifuncionais com atividade de glicocerebrosidase
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
CA2485166A1 (fr) 2002-05-21 2003-12-04 Amgen Inc. Composes heterocycliques substitues et leurs procedes d'utilisation
US8420087B2 (en) 2004-01-05 2013-04-16 Antisoma Research Limited Interleukin-12 targeted to oncofoetal fibronectin
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US8227408B2 (en) 2005-09-07 2012-07-24 Neurotez, Inc. Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
EP3521311A1 (fr) 2008-04-11 2019-08-07 Chugai Seiyaku Kabushiki Kaisha Molécule se liant à des antigènes capable de se lier à deux ou plusieurs molécules d'antigène de manière répétée
EP2326339A4 (fr) 2008-05-21 2012-06-20 Neurotez Inc Procédés de traitement de troubles cognitifs progressifs liés à la dégénérescence neurofibrillaire
WO2009149379A2 (fr) 2008-06-05 2009-12-10 Regents Of The University Of Michigan Utilisation de leptine pour le traitement de maladies et affections de stéatose hépatique
EP2352510A4 (fr) 2008-11-04 2012-08-29 Neurotez Inc Compositions à base de leptine et méthodes de traitement de troubles évolutifs de la fonction cognitive provoqués par une accumulation d enchevêtrements neurofibrillaires et de bêta-amyloïde
KR20120030383A (ko) 2009-04-22 2012-03-28 메르크 파텐트 게엠베하 변형된 ＦｃＲｎ 결합 자리를 갖는 항체 융합 단백질
CA2819356C (fr) * 2010-11-30 2023-01-24 Chugai Seiyaku Kabushiki Kaisha Molecule de liaison a l'antigene, apte a se lier de facon repetee a une pluralite de molecules d'antigene
SG10201609665PA (en) 2011-02-25 2017-01-27 Chugai Pharmaceutical Co Ltd FcɣRIIb-SPECIFIC Fc ANTIBODY
WO2013047748A1 (fr) 2011-09-30 2013-04-04 中外製薬株式会社 Molécule se liant à l'antigène favorisant la disparition des antigènes ayant une pluralité d'activités biologiques
LT2900230T (lt) 2012-09-27 2019-01-10 The Children`S Medical Center Corporation Junginiai, skirti nutukimo gydymui ir jų panaudojimo būdai
TR201901299T4 (tr) 2013-11-26 2019-02-21 Childrens Medical Ct Corp Obezite tedavisine yönelik bileşikler ve bunların kullanım yöntemleri.
US20170209408A1 (en) 2014-04-03 2017-07-27 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
NZ730607A (en) 2014-12-19 2022-07-01 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
ES2899894T3 (es) 2014-12-19 2022-03-15 Chugai Pharmaceutical Co Ltd Anticuerpos anti-C5 y métodos de uso
EA201791754A1 (ru) 2015-02-05 2019-01-31 Чугаи Сейяку Кабусики Кайся АНТИТЕЛА, СОДЕРЖАЩИЕ ЗАВИСЯЩИЙ ОТ КОНЦЕНТРАЦИИ ИОНОВ АНТИГЕНСВЯЗЫВАЮЩИЙ ДОМЕН, ВАРИАНТЫ Fc-ОБЛАСТИ, IL-8-СВЯЗЫВАЮЩИЕ АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ
JP7141336B2 (ja) 2015-12-25 2022-09-22 中外製薬株式会社 抗ミオスタチン抗体および使用方法
CN109689099B (zh) 2016-08-05 2023-02-28 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
PT3509624T (pt) 2016-09-12 2023-08-28 Amryt Pharmaceuticals Inc Métodos de deteção de anticorpos neutralizantes anti-leptina
JP7191833B2 (ja) 2017-01-30 2022-12-19 中外製薬株式会社 抗スクレロスチン抗体およびその使用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559208A (en) * 1995-01-31 1996-09-24 Eli Lilly And Company Anti-obesity proteins
GB9511935D0 (en) * 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound
RU2178307C2 (ru) * 1995-12-27 2002-01-20 Джинентех Инк. Производные ов-протеина
EA004790B1 (ru) * 1996-12-20 2004-08-26 Амген Инк. Композиции на основе слитого белка ов и способы их применения

Also Published As

Publication number Publication date
CN1274289A (zh) 2000-11-22
EP0977583B1 (fr) 2002-09-04
ES2183351T3 (es) 2003-03-16
IL132380A0 (en) 2001-03-19
CN1202862C (zh) 2005-05-25
EP0977583A1 (fr) 2000-02-09
DE69807679T2 (de) 2003-07-31
HUP0002831A2 (hu) 2000-12-28
JP2002512612A (ja) 2002-04-23
WO1998046257A8 (fr) 2000-01-27
WO1998046257A1 (fr) 1998-10-22
HUP0002831A3 (en) 2005-11-28
DE69807679D1 (de) 2002-10-10
CA2286098A1 (fr) 1998-10-22
ATE223229T1 (de) 2002-09-15
AU7132798A (en) 1998-11-11
HU226175B1 (en) 2008-06-30
JP4086908B2 (ja) 2008-05-14
CA2286098C (fr) 2009-07-07

Similar Documents

Publication Publication Date Title
HK1023513A1 (en) Compositions comprising conjugates of stable, active, human ob protein with antibody fc chain and methods
NZ332625A (en) Concentrated antibody preparation containing greater than 100 mg/ml of the antibody
DE69432758D1 (en) Therapeutisch wirksame peptidderivate
CO4830493A1 (es) Anticuerpos contra cd40 humano
NZ512083A (en) Methods of increasing lean tissue mass using OB protein compositions
EP1439193A3 (fr) Anticorps contre la heparanase
GR3036906T3 (en) Monoclonal antibody which specifically binds to tumor vascular endothelium and uses thereof.
EP1329459A3 (fr) Anticorps monoclonaux contre le récepteur d'interféron avec une activité contre l'interféron du type I
CA2246715A1 (fr) Variant d'anticorps
PT969873E (pt) Hidrato de carbono glicopeptido antigene multiplo, vacina abrangendo o mesmo e seu uso
AU2236795A (en) Afamin: a human serum albumin-like protein
WO1999024835A3 (fr) Immuno-essai pour propeptide de procollagene iii a terminal c
DE59608073D1 (de) Antikörper gegen ein, einen histidin-anteil aufweisendes fusionspolypeptid
EP0601318A3 (fr) Procédé de préparation de conjugués d'un membre spécifique d'une réaction et d'une proteine glycosylée.
ES2170161T3 (es) Nuevos conjugados de principios activos y proteinas.
AU3283693A (en) Specific antibodies against activated platelets, the preparation thereof and the use thereof in diagnosis and therapy
ATE293996T1 (de) Lage-spezifische markierung von disulfide- enthaltenden zielgerichteten vektoren
AU2002300605A1 (en) Compositions Comprising Conjugates of Stable, Active, Human OB Protein with Antibody FC Chain and Methods
NZ314010A (en) A method of targeting intracellular binding proteins using a lipidized antibody

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20120416